Allahgholipour, Amirreza
Mayo Clinic
Student Research Committee, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Citations 2
The Use of Remdesivir in Patients with COVID-19
Afshar, Zeinab Mohseni , Hosseinzadeh, Dariush , Hosseinzadeh, Rezvan , Allahgholipour, Amirreza , Sio, Terence T. , Sullman, Mark J. M. , Carson‐Chahhoud, Kristin , Barary, Mohammad , Ebrahimpour, Soheil , Babazadeh, Arefeh , Allahgholipour, Amirreza , Sio, Terence T , Sullman, Mark J M , Carson-Chahhoud, Kristin , Barary, Mohammad , Ebrahimpour, Soheil
Infectious Disorders - Drug Targets | May 11, 2023 | Volume: 23 | Issue: 7 | Pages: No page available
10.2174/1871526523666230509110907
Abstract: Remdesivir has appeared to be the most effective medication against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is broadly administered to coronavirus disease 2019 (COVID-19) patients around the world. Remdesivir is an RNA polymerase inhibitor with a broad spectrum of antiviral activities against RNA viruses in in-vitro and in-vivo models of SARSCoV, the Middle East respiratory syndrome (MERS), and SARS-CoV-2. Remdesivir is the first Food and Drug Administration (FDA) approved anti-SARS-CoV-2 treatment for adult and pediatric patients and has been used for not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. However, questions have been raised about the value of remdesivir in treating COVID-19, and governing bodies worldwide have been hesitant to approve this medication. Nevertheless, in the context of the public health emergency and the urgent need for effective treatments for patients with COVID-19, remdesivir has been approved by several authorities worldwide. Here, we discuss the characteristics and applications of remdesivir, and various challenging studies with different outcomes about its efficacy are also reviewed.
The role of cytokines and their antagonists in the treatment of COVID‐19 patients
Afshar, Zeinab Mohseni , Barary, Mohammad , Pirzaman, Ali Tavakoli , Hosseinzadeh, Rezvan , Alijanpour, Amirmasoud , Allahgholipour, Amirreza , Miri, Seyed Rouhollah , Sio, Terence T. , Sullman, Mark J. M. , Carson‐Chahhoud, Kristin , Ebrahimpour, Soheil , Mohseni Afshar, Zeinab , Babazadeh, Arefeh , Tavakoli Pirzaman, Ali , Hosseinzadeh, Rezvan , Alijanpour, Amirmasoud , Allahgholipour, Amirreza , Miri, Seyed Rouhollah , Sio, Terence T , Sullman, Mark J M , Carson-Chahhoud, Kristin , Ebrahimpour, Soheil , Barary, Mohammad
Reviews in Medical Virology | May 27, 2022 | Volume: 33 | Issue: 1 | Pages: No page available
AbstractThe coronavirus disease 2019 (COVID‐19) has various presentations, of which immune dysregulation or the so‐called cytokine storm syndrome (COVID‐CSS) is prominent. Even though cytokines are vital regulators of body immunoinflammatory responses, their exaggerated release can be harmful. This hyperinflammatory response is more commonly observed during severe COVID‐19 infections, caused by the excessive release of pro‐inflammatory cytokines, such as interleukin‐1 (IL‐1), IL‐6, IL‐8, tumour necrosis factor, granulocyte‐macrophage colony‐stimulating factor, and interferon‐gamma, making their blockers and antagonists of great interest as therapeutic options in this condition. Thus, the pathophysiology of excessive cytokine secretion is outlined, and their most important blockers and antagonists are discussed, mainly focussing on tocilizumab, an interleukin‐6 receptor blocker approved to treat severe COVID‐19 infections.